Colinz Laboratories Ltd
₹ 46.2
5.00%
25 May
- close price
About
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations[1]
Key Points
- Market Cap ₹ 5.82 Cr.
- Current Price ₹ 46.2
- High / Low ₹ 87.9 / 36.1
- Stock P/E 11.4
- Book Value ₹ 39.9
- Dividend Yield 0.00 %
- ROCE 7.20 %
- ROE 5.23 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.16 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -0.07% over past five years.
- Company has a low return on equity of 5.45% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 6.14 | |
| 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.72 | |
| Operating Profit | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.42 |
| OPM % | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 6.84% |
| 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.48 | |
| Interest | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.16 |
| Profit before tax | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.69 |
| Tax % | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | 24.64% |
| 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.51 | |
| EPS in Rs | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.83 | 1.95 | 1.98 | 2.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 19% |
| 3 Years: | 2% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 27% |
| 3 Years: | 6% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.52 |
| 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.39 | |
| 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 2.35 | |
| Total Liabilities | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 |
| 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.54 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.11 |
| 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 10.13 | |
| Total Assets | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.40 | 1.03 | -1.45 | 0.00 | |
| 0.03 | 0.00 | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | 0.01 | 0.01 | -0.23 | 0.00 | |
| 0.45 | -0.73 | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | 0.24 | 0.00 | |
| Net Cash Flow | 0.57 | -0.16 | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 | 0.52 | 1.27 | -1.45 | 0.00 |
| Free Cash Flow | 0.09 | 0.58 | 0.04 | 0.34 | 0.12 | 0.54 | 2.00 | 0.43 | 0.40 | 1.03 | -1.71 | 0.00 |
| CFO/OP | 26% | 136% | 22% | 106% | 43% | 210% | 659% | 105% | 89% | 224% | -253% | 0% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 | 49.93 |
| Inventory Days | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 | 149.42 |
| Days Payable | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 | 81.11 |
| Cash Conversion Cycle | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 | 118.24 |
| Working Capital Days | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 72.66 | -60.64 |
| ROCE % | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% | 7.20% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Permanent Employees number |
|
|||||
| Net Capital Turnover Ratio times |
||||||
| Trade Payable Turnover Ratio times |
||||||
| Trade Receivables Turnover Ratio times |
||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 7h
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
7h - Vijaya Mani sold 3,78,000 shares off-market on May 21, 2026; holding fell to 34.56%.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 12h
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
13h - Vijaya Mani sold 3,78,000 shares off-market on May 21, 2026; holding fell to 34.56% from 49.56%.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Apr - Dear Sir, We have Publsihed our Outcome of Mar-26 Results as requred under Regulation 47(3) of SEBI(LODR), Regulations,2015 in 1) FREE PRESS JOURNAL 2) NAV …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
http://www.colinz.com/about.html
CLL is a manufacturer and exporter of pharmaceutical formulations for allopathic, ayurvedic, nutraceticals in dosage forms of tablets, capsules, ointments, creams, granules, liquid, orals, injectables, syrups, suppsitories, etc. It also has certain specialized products for Gynaecology, cardiology, gastroenterology, etc.